Envisioning the future of precision oncology trials
Authors:
- 4 January 2021
- journal article
- editorial
- Published by Springer Nature in Nature Cancer
- Vol. 2 (1) , 9-11
Abstract
No abstract availableKeywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30 CA51008)
This publication has 13 references indexed in Scilit:
- Collaborative, Multidisciplinary Evaluation of Cancer Variants Through Virtual Molecular Tumor Boards Informs Local Clinical PracticesJCO Clinical Cancer Informatics, 2020
- The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell ResolutionCell, 2020
- Support of a molecular tumour board by an evidence-based decision management system for precision oncologyEuropean Journal of Cancer, 2020
- A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patientsJAMIA Open, 2019
- An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome AnalyticsCell, 2018
- Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancerESMO Open, 2018
- Precision oncology: origins, optimism, and potentialThe Lancet Oncology, 2016
- NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:JNCI: Journal of the National Cancer Institute, 2015
- The CPTAC Data Portal: A Resource for Cancer Proteomics ResearchJournal of Proteome Research, 2015
- Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)Journal of Clinical Oncology, 2009